210 related articles for article (PubMed ID: 34888676)
21. Antidiabetic Treatment, Level of Glycemic Control, and Risk of Fracture in Type 2 Diabetes: a Nested, Case-Control Study.
Charlier S; Vavanikunnel J; Becker C; Jick SS; Meier C; Meier CR
J Clin Endocrinol Metab; 2021 Jan; 106(2):554-566. PubMed ID: 33141149
[TBL] [Abstract][Full Text] [Related]
22. Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
Bachmann KN; Roumie CL; Wiese AD; Grijalva CG; Buse JB; Bradford R; Zalimeni EO; Knoepp P; Dard S; Morris HL; Donahoo WT; Fanous N; Fonseca V; Katalenich B; Choi S; Louzao D; O'Brien E; Cook MM; Rothman RL; Chakkalakal RJ
Pharmacol Res Perspect; 2020 Oct; 8(5):e00637. PubMed ID: 32881317
[TBL] [Abstract][Full Text] [Related]
23. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
Josse RG; Majumdar SR; Zheng Y; Adler A; Bethel MA; Buse JB; Green JB; Kaufman KD; Rodbard HW; Tankova T; Westerhout CM; Peterson ED; Holman RR; Armstrong PW;
Diabetes Obes Metab; 2017 Jan; 19(1):78-86. PubMed ID: 27607571
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
Melzer Cohen C; Davis C; Shalev V; Chodick G
J Diabetes; 2018 Jan; 10(1):68-72. PubMed ID: 28418203
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Lim S; Han KA; Yu J; Chamnan P; Kim ES; Yoon KH; Kwon S; Moon MK; Lee KW; Kim DJ; Kim M; Wongtanate M; Kim EY; Kim SH; Lee MK;
Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
[TBL] [Abstract][Full Text] [Related]
26. Clinical Determinants of Diabetes Progression in Multiethnic Asians with Type 2 Diabetes - A 3-Year Prospective Cohort Study.
Liu S; Liu JJ; Gurung RL; Chan C; Yeo D; Ang K; Tang WE; Tavintharan S; Sum CF; Lim SC
Ann Acad Med Singap; 2019 Jul; 48(7):217-223. PubMed ID: 31495867
[TBL] [Abstract][Full Text] [Related]
27. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
28. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
Dailey GE; Mohideen P; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
[TBL] [Abstract][Full Text] [Related]
29. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
Driessen JH; van den Bergh JP; van Onzenoort HA; Henry RM; Leufkens HG; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):421-428. PubMed ID: 27943565
[TBL] [Abstract][Full Text] [Related]
30. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
[TBL] [Abstract][Full Text] [Related]
31. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
Rathmann W; Bongaerts B; Kostev K
Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
[TBL] [Abstract][Full Text] [Related]
32. Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database.
Farmer AJ; Rodgers LR; Lonergan M; Shields B; Weedon MN; Donnelly L; Holman RR; Pearson ER; Hattersley AT
Diabetes Care; 2016 Feb; 39(2):258-263. PubMed ID: 26681714
[TBL] [Abstract][Full Text] [Related]
33. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
34. Association Between Type 2 Diabetes and All-Cause Hospitalization and Mortality in the UK General Heart Failure Population: Stratification by Diabetic Glycemic Control and Medication Intensification.
Lawson CA; Jones PW; Teece L; Dunbar SB; Seferovic PM; Khunti K; Mamas M; Kadam UT
JACC Heart Fail; 2018 Jan; 6(1):18-26. PubMed ID: 29032131
[TBL] [Abstract][Full Text] [Related]
35. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
36. A Prospective Analysis of the Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors: Real World Evidence from Clinical Practice in India.
Sosale B; Sosale AR; Kumar PM; Joshi SR
J Assoc Physicians India; 2016 Sep; 64(9):40-44. PubMed ID: 27762514
[TBL] [Abstract][Full Text] [Related]
37. Is insulin the preferred treatment for HbA1c >9%?
Bloomgarden Z
J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis.
Sharma M; Beckley N; Nazareth I; Petersen I
BMJ Open; 2017 Oct; 7(10):e017260. PubMed ID: 29084794
[TBL] [Abstract][Full Text] [Related]
39. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
[TBL] [Abstract][Full Text] [Related]
40. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
Goldenberg RM
Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
